Latrepirdine not effective in Huntington's disease

November 1, 2012
Latrepirdine not effective in huntington's disease
Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease, according to a study published online Oct. 29 in the Archives of Neurology.

(HealthDay)—Although safe and well tolerated, the experimental small molecule latrepirdine does not improve cognition after six months of treatment in patients with mild-to-moderate Huntington's disease (HD), according to a study published online Oct. 29 in the Archives of Neurology.

Karl Kieburtz, M.D., M.P.H., and colleagues from the HORIZON Investigators of the Study Group and the European Huntington's Disease Network, conducted a six-month, randomized, double-blind study of latrepirdine, 20 mg three times daily, versus placebo in 403 patients with mild-to-moderate HD, across 64 research centers in Australia, Europe, and North America. The effect of latrepirdine on cognition and global function was assessed.

The researchers observed no significant difference between latrepirdine-treated patients and placebo-treated patients in the mean change in the Mini-Mental State Examination score (1.5- and 1.3-point improvement, respectively). There was also no significant difference in the distribution of the Clinician Interview-Based Impression of Change, plus carer interview between the groups (P = 0.84). There were no significant differences on secondary efficacy outcomes measures of behavior, daily function, motor function, and safety. There was a similar incidence of adverse events for latrepirdine- and placebo-treated patients.

"In patients with mild-to-moderate HD and , treatment with latrepirdine for six months was safe and well tolerated but did not improve cognition or global function relative to placebo," the authors write.

Several authors disclosed to pharmaceutical companies, including Medivation and Pfizer, both of which supported the study and manufacture latrepirdine.

Explore further: Evidence lacking for efficacy of memantine in treating mild Alzheimer's disease

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Reach2HD, a Phase II study in Huntington's disease, launched

June 7, 2012

The Huntington Study Group (HSG), under the leadership of Ray Dorsey, M.D. with Johns Hopkins Medical and Diana Rosas, M.D. with Massachusetts General Hospital, is conducting a clinical trial in Huntington's disease (HD) ...

Rejected Alzheimer's drug shows new potential

July 31, 2012

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped ...

Donepezil found helpful in dementia with lewy bodies

July 31, 2012

(HealthDay) -- For patients with dementia with Lewy bodies (DLB), treatment with 5 or 10 mg/day donepezil is associated with significant cognitive, behavioral, and global function improvements, according to research published ...

Recommended for you

Action recognition without mirror neurons

April 29, 2016

When someone stands opposite us and purposefully raises their arm to make some kind of movement, our brain asks itself whether they intend to attack us or, perhaps, simply greet us. Scientists from the Department of Human ...

Subtle chemical changes in brain can alter sleep-wake cycle

April 28, 2016

A study out today in the journal Science sheds new light on the biological mechanisms that control the sleep-wake cycle. Specifically, it shows that a simple shift in the balance of chemicals found in the fluid that bathes ...

Turn left! How myosin-Va helps direct neuron growth

April 28, 2016

Researchers at the RIKEN Brain Science Institute in Japan have discovered a protein complex that helps direct the growth of axons—the parts of neurons that make up our nerves, connecting our senses and muscles to the brain ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.